

**Unaudited Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31, 2023 and 2022** 

(Expressed in United States Dollars)

# Micromem Technologies Inc. Unaudited Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States Dollars)

# **Contents**

Notice to Shareholders	1
Unaudited Condensed Interim Consolidated Financial Statements:	
Unaudited Condensed Interim Consolidated Statements of Financial Position	2
Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss)	3
Unaudited Condensed Interim Consolidated Statements of Changes in Equity	4
Unaudited Condensed Interim Consolidated Statements of Cash Flows	5
Notes to the Unaudited Condensed Interim Consolidated Financial Statements	6

Unaudited Condensed Interim Consolidated Financial Statements Notice of no auditor review of the condensed interim consolidated financial statements

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that the condensed interim consolidated financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim consolidated financial statements of Micromem Technologies Inc. (the "Company") have been prepared by and are the responsibility of the Company's management and approved by the Board of Directors.

The Company's independent auditor has not performed a review of these condensed interim consolidated financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada, for a review of condensed interim consolidated financial statements by an entity's auditor.

September 19, 2023

# Unaudited Condensed Interim Consolidated Statements of Financial Position As at July 31, 2023 and October 31, 2022

(Expressed in United States dollars)

Approved on behalf of the Board of Directors:

	Notes	As at July 31, 2023		Oc	As at tober 31, 2022
Assets					
Current					
Cash	19(a)(d)	\$	182,826	\$	33,227
Prepaid expenses and other receivables			21,451		18,200
Total current assets			204,277		51,427
Property and equipment	5		36,331		48,092
Total assets		\$	240,608	\$	99,519
Liabilities					
Current					
Trade payables and other liabilities	19(a)(c)	\$	103,830	\$	287,575
Current lease liability	7		17,428		15,366
Debenture payable Convertible debentures	10 9		39,486 3,479,341		38,001 3,792,064
Derivative liabilities	9		2,712,524		641,299
Total current liabilities	,		6,352,609		4,774,305
Non-current lease liability	7		17,369		29,418
Long-term loan	8		45,534		43,796
	o				
Total liabilities			6,415,512		4,847,519
Shareholders' Deficiency					
Share capital	11		90,466,902		87,784,725
Contributed surplus	12		25,418,211		27,459,730
Equity component of convertible debentures	9		2,648,330		793,140
Accumulated deficit			(124,708,347)		(120,785,595)
Total shareholders' deficiency			(6,174,904)		(4,748,000)
Total liabilities and shareholders' deficiency		\$	240,608	\$	99,519
Going concern	2				
Contingencies	18				
Subsequent events	22				

"Joseph Fuda"	_"Alex Dey"
Director	Director

# Micromem Technologies Inc. Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss) For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars)

		Three months	ended	• ,		Nine months ended July 31,			
	Notes	 2023		2022		2023		2022	
Operating expenses									
General and administrative	15(a)	\$ 40,957	\$	44,816	\$	112,915	\$	156,946	
Professional, other fees and salaries	15(b)	186,036		178,173		382,338		503,988	
Stock-based compensation	12	-		-		151,406		952	
Travel and entertainment		24,838		21,788		48,698		37,040	
Amortization of property and equipment									
	5	4,170		7,185		12,341		21,557	
Amortization of patents	6	-		-		-		3,877	
Foreign exchange loss (gain)	19(a)	 140,395		125,218		58,016		160,342	
Total operating expenses		 396,396		377,180		765,714		884,702	
Other expenses									
Accretion expense	9	67,750		422,219		221,801		1,677,162	
Interest expense on convertible debt	9	131,233		124,270		399,573		350,366	
Other finance expenses Loss (gain) on revaluation of derivative	7,10	22,403		2,812		57,154		9,844	
liabilities Loss (gain) on conversion of convertible	9	(705,297)		791,725		573,248		(297,743)	
debentures Loss (gain) on repayment of convertible	9	-		(266,391)		21,120		67,505	
debentures Loss (gain) on extinguishment of	9	(14,967)		-		(33,349)		-	
convertible debentures	9	(47,130)		(30,642)		1,957,491		14,341	
Total other expenses		(546,008)		1,043,993		3,197,038		1,821,475	
Income (loss) before income tax provision		149,612		(1,421,173)		(3,962,752)		(2,706,177)	
Income tax provision Net income (loss) and comprehensive	14	 		-	_	-		-	
income (loss)		\$ 149,612	\$	(1,421,173)	\$	(3,962,752)	\$	(2,706,177)	
Net income (loss) attributable to common shareholders									
Basic		\$ 149,612	\$	(1,421,173)	\$	(3,962,752)	\$	(2,706,177)	
Diluted		\$ 235,935	\$	(1,421,173)	\$	(3,962,752)	\$	(2,706,177)	
Weighted average number of outstanding shares	13								
Basic		503,800,902		426,218,016		480,136,985		447,023,410	
Diluted		597,076,829		426,218,016		480,136,985		447,023,410	
Income (loss) per share, basic and diluted	13								
Basic		\$ 0.00	\$	(0.00)	\$	(0.01)	\$	(0.01)	
Diluted		\$ 0.00	\$	(0.00)	\$	(0.01)	\$	(0.01)	

# Unaudited Condensed Interim Consolidated Statements of Changes in Equity For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars)

	Notes	Number of shares	S	hare capital	(	Contributed surplus	c	Equity mponent of onvertible ebentures	1	Accumulated deficit		Total
										(4.4.0.4.0.0.7.0.0)		
Balance at November 1, 2021		435,737,734	\$	86,815,836	\$	28,197,382	\$	14,004	\$	(118,498,500)	\$	(3,471,278)
Private placements of shares for cash Convertible debentures converted into	11	4,513,674		195,225		-		-		-		195,225
common shares Expiry of convertible debenture conversion	9	18,834,053		506,712		-		-		-		506,712
option	9	-		-		11,043		(11,043)		-		-
Renewal of convertible debentures	9	-		-		-		11,043		-		11,043
Stock-based compensation	12	-		-		952		-		-		952
Net income (loss)										(2,706,177)		(2,706,177)
Balance at July 31, 2022		459,085,461	\$	87,517,773	\$	28,209,377	\$	14,004	\$	(121,204,677)	\$	(5,463,523)
Balance at November 1, 2022	ī	467,607,678	\$	87,784,725	\$	27,459,730	\$	793,140	\$	(120,785,595)	\$	(4,748,000)
Private placements of shares for cash Convertible debentures converted into	11	9,239,500		498,690		-		-		-		498,690
common shares	9	27,288,959		1,748,665		-		(77,052)		-		1,671,613
Exercise of options	12	2,550,000		434,822		(220,683)		-		-		214,139
Expiry of options	12	-		-		(40,000)		-		40,000		-
Expiry of convertible debenture conversion	9					793,140		(793,140)				
option  Renewal of convertible debentures	9	-		-		(2,725,382)		2,725,382		-		-
Stock-based compensation	9 12	-		-		151,406		2,123,362		-		151,406
•	12	_		_		131,700		_		(2.062.752)		ŕ
Net income (loss)	•	-		-	Φ.		Φ.		Φ.	(3,962,752)	Φ.	(3,962,752)
Balance at July 31, 2023	i	506,686,137		90,466,902	\$	25,418,211	\$	2,648,330	\$	(124,708,347)	\$	(6,174,904)

# Unaudited Condensed Interim Consolidated Statements of Cash Flows For the nine months ended July 31, 2023 and 2022

(Expressed in United States dollars)

	Notes		July 31 2022		
Operating activities		_		_	
Net income (loss)		\$	(3,962,752)	\$	(2,706,177)
Items not affecting cash:	_		10 241		21 557
Amortization of property and equipment	5		12,341		21,557
Amortization of patents	6		221 901		3,877
Accretion expense	9,16		221,801		1,677,162
Accrued interest on convertible debentures	9,16		347,701		265,004
Stock-based compensation	12		151,406		952
Loss (gain) on conversion of convertible debentures	9,16		21,120		67,505
Loss (gain) on repayment of convertible debentures	9,16		(33,349)		(207.742)
Loss (gain) on revaluation of derivative liabilities	9,16		573,248		(297,743)
Loss (gain) on extinguishment of convertible debentures	9,16		1,957,491		14,341
Foreign exchange loss (gain)	19(a)		61,353		183,808
			(649,640)		(769,714)
Net changes in non-cash working capital:			(2.271)		(515)
Prepaid expenses and other receivables			(3,251)		(517)
Trade payables and other liabilities			(183,745)		(24,678)
Cash flows used in operating activities			(836,636)		(794,909)
Investing activity					
Purchase of property and equipment	5		(1,176)		_
Cash flows used in investing activity			(1,176)		
			· · · · · ·		
Financing activities					
Principal payments on lease liability	7		(11,521)		(24,788)
Private placements of shares for cash	11		498,690		195,225
Exercise of options	12		214,139		-
Proceeds from issuance of convertible debentures	16		429,103		572,600
Repayments of convertible debentures	16		(143,000)		(50,990)
Cash flows provided by financing activities			987,411		692,047
Net change in cash			149,599		(102,862)
Cash - beginning of period			33,227		171,397
Cash - end of period		\$	182,826	\$	68,535
Supplemental cash flow information		_	.= -10		
Interest paid (classified in operating activities)	9	\$	47,218	\$	75,802
Interest converted (classified in operating activities)	9	\$	278,204	\$	9,560
Interest paid on non-convertible debt (classified in operating					
activities)	10	\$	6,874	\$	-
Interest paid on lease liability (classified in operating activities)	7	\$	2,630	\$	2,583
Carrying amount of convertible debentures converted into			,	•	
common shares	9	\$	1,748,665	\$	506,712
	-		, -,		- y - <del>-</del>

Micromem Technologies Inc. Notes to the Unaudited Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

#### 1. Reporting entity and nature of business

Micromem Technologies Inc. ("Micromem" or the "Company") is incorporated under the laws of the Province of Ontario, Canada. Micromem is a publicly traded company with its head office located at 121 Richmond Street West, Suite 602, Toronto, Ontario, Canada. The Company's common shares are currently listed on the Canadian Securities Exchange under the trading symbol "MRM" and on the Over the Counter Venture Market under the trading symbol "MMTIF".

The Company develops, based upon proprietary technology, customized sensor applications for companies (referred to as "Development Partners") operating internationally in various industry segments. The Company has not generated commercial revenues through July 31, 2023 and is devoting substantially all its efforts to securing commercial revenue opportunities.

#### 2. Going concern

These unaudited condensed interim consolidated financial statements have been prepared with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

There are material uncertainties related to conditions and events that cast substantial doubt about the Company's ability to continue as a going concern and ultimately on the appropriateness of the use of the accounting principles applicable to a going concern. During the nine months ended July 31, 2023, the Company reported a net loss and comprehensive loss of \$3,962,752 (2022 - \$2,706,177) and negative cash flow from operations of \$836,636 (2022 - \$794,909). The Company's working capital deficiency as at July 31, 2023 was \$6,148,332 (October 31, 2022 – \$4,722,878).

The Company's success depends on the profitable commercialization of its proprietary sensor technology. Based upon its current operating and financial plans, management of the Company believes that it will have sufficient access to financial resources to fund the Company's planned operations through the next twelve months; however, the ability of the Company to continue as a going concern is dependent upon its ability to secure additional financing and/or to profitably commercialize its technology. There is no assurance that the Company will be successful in the profitable commercialization of its technology, or will be able to secure the necessary additional financing. These unaudited condensed interim consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. If the going concern assumption was not appropriate for these unaudited condensed interim consolidated financial statements then adjustments could be necessary to the carrying value of assets and liabilities, the reported expenses and the statement of financial position classifications used; in such cases, these adjustments could be material.

# 3. Basis of presentation

These unaudited condensed interim consolidated financial statements for the three and nine months ended July 31, 2023 and 2022 have been prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting. The accounting policies and methods of computation adopted in the preparation of the unaudited condensed interim consolidated financial statements are consistent with those followed in the preparation of the Company's audited annual consolidated financial statements for the year ended October 31, 2022. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

These unaudited condensed interim consolidated financial statements were authorized for issuance and release by the Company's Board of Directors on September 19, 2023

# (a) Basis of consolidation

These unaudited condensed interim consolidated financial statements include the accounts of Micromem Technologies Inc. and its subsidiaries. All intercompany transactions and balances have been eliminated upon consolidation.

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

#### 3. Basis of presentation (continued)

#### (a) Basis of consolidation (continued)

The Company's wholly-owned subsidiaries include:

(i)	Inactive	Domiciled in
	Micromem Applied Sensors Technology Inc. ("MAST")	United States
	707019 Canada Inc.	Canada
	Memtech International Inc.	Bahamas
	Memtech International (USA) Inc., Pageant Technologies (USA) Inc.	United States
	Pageant Technologies Inc., Micromem Holdings (Barbados) Inc.	Barbados

#### (b) Basis of measurement

These unaudited condensed interim consolidated financial statements have been prepared on the historical cost basis, except for financial instruments designated at fair value through profit and loss which are measured at their fair value.

#### (c) Functional and presentation currency

These unaudited condensed interim consolidated financial statements are presented in United States dollars ("USD"), which is the functional currency of the Company and all of its subsidiaries.

#### (d) Use of estimates and judgments

The preparation of these unaudited condensed consolidated interim financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited condensed interim consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates are reviewed periodically and adjustments are made as appropriate in the reporting period they become known. Items for which actual results may differ materially from these estimates are described in the following section.

#### (i) Fair value of options and conversion features

The Company makes estimates and utilizes assumptions in determining the fair value for stock options and conversion features based on the application of the Black-Scholes option pricing model or the binomial option pricing model, depending on the circumstances. These pricing models require management to make various assumptions and estimates that are susceptible to uncertainty, including the volatility of the share price, expected dividend yield, expected term, risk-free interest rate, and exercise price in the binomial option pricing model.

# (ii) Useful lives and recoverability of long-lived assets

Long-lived assets consist of property and equipment and patents. Amortization is dependent upon estimates of useful lives and impairment is dependent upon estimates of recoverable amounts. These are determined through the exercise of judgment and are dependent upon estimates that take into account factors such as economic and market conditions, frequency of use, anticipated changes in laws, and technological improvements.

#### (iii) Income taxes

Income taxes and tax exposures recognized in the unaudited condensed interim consolidated financial statements reflect management's best estimate of the outcome based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference.

When the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future, based on budgeted forecasts. These forecasts are adjusted for certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences.

#### (iv) Going concern assumption

The Company applies judgment in assessing whether material uncertainties exist that would cause doubt as to the whether the Company could continue as a going concern.

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

# 4. New and revised standards and interpretations

Certain pronouncements were issued by the IASB or the IFRIC that are mandatory for accounting periods commencing on or after November 1, 2022. The Company has adopted these pronouncements as of their effective date, and many are not applicable or do not have a significant impact on the Company and have been excluded.

The following amendments were issued but not yet effective. The Company will adopt these amendments as of their effective dates. The Company is currently assessing the impacts of adoption.

#### (a) Amendments to IAS 1, Presentation of Financial Statements

IAS 1 was amended in January 2020 to provide a more general approach to the classification of liabilities under IAS 1 based on the contractual arrangements in place at the reporting date. The amendments clarify that the classification of liabilities as current or noncurrent is based solely on a company's right to defer settlement at the reporting date. The right needs to be unconditional and must have substance. The amendments also clarify that the transfer of a company's own equity instruments is regarded as settlement of a liability, unless it results from the exercise of a conversion option meeting the definition of an equity instrument. The amendments are effective for annual periods beginning on January 1, 2023

In February 2021, the IASB issued 'Disclosure of Accounting Policies' with amendments that are intended to help preparers in deciding which accounting policies to disclose in their financial statements. The amendments are effective for year ends beginning on or after January 1, 2023.

#### (b) Amendment to IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors

In February 2021, the International Accounting Standards Board ("IASB") issued 'Definition of Accounting Estimates' to help entities distinguish between accounting policies and accounting estimates. The amendment is effective for annual reporting periods beginning on or after January 1, 2023. Earlier adoption is permitted.

#### (c) Amendments to IAS 12, Income Taxes

In May 2021, the IASB issued 'Deferred Tax Related to Assets and Liabilities Arising from a Single Transaction' that clarifies how entities account for deferred tax on transactions such as leases and decommissioning obligations. The amendments are effective for year ends beginning on or after January 1, 2023.

#### (d) Amendments to IFRS 10, Consolidated Financial Statements and IAS 28, Investments in Associates and Joint Ventures

IFRS 10 and IAS 28 were amended in September 2014 to address a conflict between the requirements of IAS 28 and IFRS 10 and clarify that in a transaction involving an associate or joint venture, the extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business. The effective date of these amendments is yet to be determined, however early adoption is permitted.

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

# 5. Property and equipment

Cost	No	As at vember 1,	A(	dditions	<u>_</u>	Disposals		reign hange	As at uly 31, 2023
Computers	\$	7,466	\$	1,176	\$	-	\$	-	\$ 8,642
Right-of-use assets		48,408		-		-		-	48,408
		55,874		1,176		=	. ,	=	57,050
Accumulated amortization									
Computers		3,748		807		-		28	4,583
Right-of-use assets		4,034		11,534		-		568	16,136
		7,782		12,341		-		596	20,719
Net book value	\$	48,092							\$ 36,331

### 6. Patents

	No	As at vember 1, 2022	A(	lditions	Dis	posals	oreign change	•	As at July 31, 2023
Cost Accumulated amortization	\$	681,288 681,288	\$		\$	- -	\$ -	\$	681,288 681,288
Net book value	\$	-	\$	-	\$	-	\$ -	\$	-

The Company holds several patents in the United States for its Multimodal Fluid Condition Sensor Platform. In prior years, the Company had negotiated with a major automotive company and a Tier 1 manufacturer for the development and commercial exploitation of this patented technology. The Company maintains that there remains significant potential value in its existing patents in terms of potential licensing agreements and royalty fees once it begins to exploit this asset class in the future.

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

#### 7. Leases

#### (a) Continuity schedule of lease obligation

The lease obligation relates to the use of office space in Toronto, Ontario. On May 26, 2022, a new lease agreement was entered into for a term from August 1, 2022 to July 31, 2025 for office space in another location in Toronto, Ontario. The present value of the lease obligation was calculated using a discount rate of 9%.

Balance, October 31, 2022	\$ 44,784
Interest expense	2,630
Lease payments	(14,151)
Foreign exchange	1,534
Balance, July 31, 2023	\$ 34,797

#### (b) Maturity analysis of lease obligations

The following represents a maturity analysis of the Company's undiscounted contractual lease obligations as at July 31, 2023:

	 CDN
Less than one year	\$ 25,965
Between one and five years	\$ 24,330

## 8. Long-term loan

As at July 31, 2023, the Company has a \$60,000 CDN (\$45,534 USD) (October 31, 2022 – \$60,000 CDN, \$43,796 USD) interest-free loan from the Government of Canada under the Canada Emergency Business Account ("CEBA") program to cover its operating costs. The term loan matures on December 31, 2025. Repaying the balance of the loan on or before December 31, 2023 will result in a loan forgiveness of \$20,000 CDN (\$15,178 USD). Effective January 1, 2024, any outstanding balance on the term loan shall bear interest at a rate of 5% per annum. As the Company does not yet know whether they will be able to meet the terms of forgiveness, no amount has been recognized in income.

# 9. Convertible debentures

The Company issues three types of convertible debentures: USD denominated convertible debentures with an equity component, Canadian dollar ("CDN") denominated convertible debentures with an embedded derivative due to variable consideration payable upon conversion caused by foreign exchange, and USD denominated convertible debentures with an embedded derivative caused by variable conversion prices.

During the three and nine months ended July 31, 2023, the Company incurred \$nil (2022 - \$nil) financing costs. All loan principal amounts and conversion prices are expressed in original currency and all remaining dollar amounts are expressed in USD.

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

# 9. Convertible debentures (continued)

(a) Current period information presented in the unaudited condensed interim consolidated financial statements

# Convertible debentures outstanding as at July 31, 2023:

		USD						
		(equity	CD	N (embedded	USI	) (embedded		
	co	mponent)		derivative)	d	erivative)		Total
Loan principal outstanding	\$	1,223,018	\$	2,023,782	\$	395,125		
Terms of loan								
Annual stated interest rate	13	2% - 24%	1	12% - 24%		2% - 4%		
Effective annual interest rate		24%		22 - 131%	24	% - 4331%		
Conversion price to common shares	\$0	.03 - \$0.07	\$0	0.05 - \$0.08		(i) - (ii)		
Remaining life (in months)		0 - 6		0 - 6		0 - 12		
Unaudited Condensed Interim Consolidated Statement of	of Finan	cial Position						
Carrying value of loan principal	\$	1,222,955	\$	1,514,128	\$	75,170	\$	2,812,253
Interest payable		345,118		293,051		28,919		667,088
Convertible debentures	\$	1,568,073	\$	1,807,179	\$	104,089	\$	3,479,341
Derivative liabilities	\$	-	\$	2,462,165	\$	250,359	\$	2,712,524
Equity component of convertible debentures	\$	2,648,330	\$	-	\$	-	\$	2,648,330
For the nine months anded July 21 2022.								
For the nine months ended July 31, 2023:		USD						
		(equity	CD	N (embedded	USI	) (embedded		
		mponent)		derivative)		erivative)		Total
		mponent)				crivative)		
Unaudited Condensed Interim Consolidated Statement of	-	_				crivative)		
Unaudited Condensed Interim Consolidated Statement of Accretion expense	-	_			\$	15,691	\$	221,801
	of Opera	ations and Co	mpre	ehensive Loss		<u> </u>	\$ \$	
Accretion expense	Opera \$ \$ \$	ations and Co	\$ \$ \$ \$	ehensive Loss 190,900	\$ \$ \$	15,691		221,801
Accretion expense Interest expense	<b>Opera</b> \$ \$ \$ \$ \$	ations and Co	\$ \$ \$ \$ \$	ehensive Loss 190,900 183,087	\$ \$ \$	15,691 9,006	\$	221,801 399,573
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities	\$ \$ \$ \$ \$ \$	ations and Co	\$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499	\$ \$ \$	15,691 9,006 (78,251)	\$ \$	221,801 399,573 573,248
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures	<b>Opera</b> \$ \$ \$ \$ \$	ations and Co 15,210 207,480	\$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499	\$ \$ \$	15,691 9,006 (78,251) 21,120	\$ \$ \$	221,801 399,573 573,248 21,120
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures (Gain) loss on repayment of convertible debentures (Gain) loss on extinguishment of convertible debentures	\$ \$ \$ \$ \$ \$ \$	15,210 207,480 - - - (14,004)	\$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499	\$ \$ \$ \$	15,691 9,006 (78,251) 21,120 (33,349)	\$ \$ \$	221,801 399,573 573,248 21,120 (33,349)
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures (Gain) loss on repayment of convertible debentures (Gain) loss on extinguishment of convertible debentures  Unaudited Condensed Interim Consolidated Statement of	of Opera \$ \$ \$ \$ \$ \$	15,210 207,480 - - (14,004) ges in Equity	\$ \$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499 - - 1,855,702	\$ \$ \$ \$ \$	15,691 9,006 (78,251) 21,120 (33,349) 115,793	\$ \$ \$	221,801 399,573 573,248 21,120 (33,349)
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures (Gain) loss on repayment of convertible debentures (Gain) loss on extinguishment of convertible debentures	\$ \$ \$ \$ \$ \$ \$	15,210 207,480 - - - (14,004)	\$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499	\$ \$ \$ \$	15,691 9,006 (78,251) 21,120 (33,349)	\$ \$ \$	221,801 399,573 573,248 21,120 (33,349)
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures (Gain) loss on repayment of convertible debentures (Gain) loss on extinguishment of convertible debentures  Unaudited Condensed Interim Consolidated Statement of Amount of principal converted to common shares  Amount of interest converted to common shares	\$ \$ \$ \$ \$ \$ \$ \$	15,210 207,480 - - - (14,004) ges in Equity 200,000	\$ \$ \$ \$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499 - 1,855,702	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	15,691 9,006 (78,251) 21,120 (33,349) 115,793	\$ \$ \$	221,801 399,573 573,248 21,120 (33,349)
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures (Gain) loss on repayment of convertible debentures (Gain) loss on extinguishment of convertible debentures  Unaudited Condensed Interim Consolidated Statement of Amount of principal converted to common shares	\$ \$ \$ \$ \$ \$ \$ \$	15,210 207,480 - - - (14,004) ges in Equity 200,000	\$ \$ \$ \$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499 - 1,855,702	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	15,691 9,006 (78,251) 21,120 (33,349) 115,793	\$ \$ \$	221,801 399,573 573,248 21,120 (33,349)
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures (Gain) loss on repayment of convertible debentures (Gain) loss on extinguishment of convertible debentures  Unaudited Condensed Interim Consolidated Statement of Amount of principal converted to common shares  Amount of interest converted to common shares  Number of common shares issued on conversion of convertible debentures	of Opera \$ \$ \$ \$ \$ of Chan;	15,210 207,480 - - - (14,004) ges in Equity 200,000 55,464 5,263,158	\$ \$ \$ \$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499 - 1,855,702 390,000 218,086	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	15,691 9,006 (78,251) 21,120 (33,349) 115,793 232,700 4,654	\$ \$ \$	221,801 399,573 573,248 21,120 (33,349) 1,957,491
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures (Gain) loss on repayment of convertible debentures (Gain) loss on extinguishment of convertible debentures  Unaudited Condensed Interim Consolidated Statement of Amount of principal converted to common shares Amount of interest converted to common shares Number of common shares issued on conversion of convertible debentures  Unaudited Condensed Interim Consolidated Statement of Convertible debentures	of Opera \$ \$ \$ \$ \$ of Chan;	15,210 207,480 - - - (14,004) ges in Equity 200,000 55,464 5,263,158	\$ \$ \$ \$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499 - 1,855,702 390,000 218,086	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	15,691 9,006 (78,251) 21,120 (33,349) 115,793 232,700 4,654	\$ \$ \$	221,801 399,573 573,248 21,120 (33,349) 1,957,491
Accretion expense Interest expense (Gain) loss on revaluation of derivative liabilities (Gain) loss on conversion of convertible debentures (Gain) loss on repayment of convertible debentures (Gain) loss on extinguishment of convertible debentures  Unaudited Condensed Interim Consolidated Statement of Amount of principal converted to common shares  Amount of interest converted to common shares  Number of common shares issued on conversion of convertible debentures	of Opera \$ \$ \$ \$ \$ of Chan; \$	15,210 207,480 - - - (14,004) ges in Equity 200,000 55,464 5,263,158	\$ \$ \$ \$ \$ \$ \$	ehensive Loss 190,900 183,087 651,499 - 1,855,702 390,000 218,086	\$ \$ \$ \$ \$ \$ \$ \$	15,691 9,006 (78,251) 21,120 (33,349) 115,793 232,700 4,654 9,548,701	\$ \$ \$ \$	221,801 399,573 573,248 21,120 (33,349) 1,957,491

<sup>(</sup>i) Conversion price defined as 75% multiplied by the average of the lowest 3 closing stock prices for the 10 trading days prior to conversion date.

<sup>(</sup>ii) Conversion price defined as 75% multiplied by the lowest stock price for the 20 trading days prior to conversion date.

### Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

# 9. Convertible debentures (continued)

(a) Current period information presented in the unaudited condensed interim consolidated financial statements (continued)

# For the three months ended July 31, 2023:

		USD								
	(equity component)		CDN (embedded derivative)		USD (embedded derivative)			Total		
Unaudited Condensed Interim Consolidated Statement of Operations and Comprehensive Loss										
Accretion expense	\$	1,438	\$	65,977	\$	335	\$	67,750		
Interest expense	\$	68,486	\$	59,584	\$	3,163	\$	131,233		
(Gain) loss on revaluation of derivative liabilities	\$	-	\$	(699,769)	\$	(5,528)	\$	(705,297)		
(Gain) loss on conversion of convertible debentures	\$	-	\$	-	\$	-	\$	-		
(Gain) loss on repayment of convertible debentures	\$	-	\$	-	\$	(14,967)	\$	(14,967)		
(Gain) loss on extinguishment of convertible debentures	\$	-	\$	(80,526)	\$	33,396	\$	(47,130)		

(b) Comparative information presented in the unaudited condensed interim consolidated financial statements

# Convertible debentures outstanding as at October 31, 2022:

	CO	(equity omponent)		N (embedded lerivative)		(embedded erivative)	Total
Loan principal outstanding	\$	1,205,144	\$	2,321,755	\$	347,700	
Terms of loan							
Annual stated interest rate	12% - 24%		12% - 24%		2	2% - 4%	
Effective annual interest rate	24%		22% - 131%		24% - 5803%		
Conversion price to common shares	\$0.03 - \$0.07		\$0.05 - \$0.08		(i) - (ii)		
Remaining life (in months)	0 - 6		0 - 10		0 - 11		
<b>Unaudited Condensed Interim Consolidated Statement of</b>	Finaı	ncial Position					
Carrying value of loan principal	\$	1,203,478	\$	1,661,742	\$	130,424	\$ 2,995,644
Interest payable		380,360		389,617		26,443	796,420
Convertible debentures	\$	1,583,838	\$	2,051,359	\$	156,867	\$ 3,792,064
Derivative liabilities	\$	-	\$	439,194	\$	202,105	\$ 641,299
Equity component of convertible debentures	\$	793,140	\$	-	\$	-	\$ 793,140

USD

<sup>(</sup>i) Conversion price defined as 75% multiplied by the average of the lowest 3 closing stock prices for the 10 trading days prior to conversion date.

<sup>(</sup>ii) Conversion price defined as 75% multiplied by the lowest stock price for the 20 trading days prior to conversion date.

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

# 9. Convertible debentures (continued)

(b) Comparative information presented in the unaudited condensed interim consolidated financial statements (continued)

# For the nine months ended July 31, 2022

Call value

		USD (equity component)		CDN (embedded derivative)		USD (embedded derivative)		Total
<b>Unaudited Condensed Interim Consolidated Statement </b>	of Opera	tions and Co	mpre	hensive Loss				
Accretion expense	\$	20,866	\$	1,648,980	\$	7,316	\$	1,677,162
Interest expense	\$	175,308	\$	171,425	\$	3,633	\$	350,366
(Gain) loss on revaluation of derivative liabilities	\$	-	\$	(752,970)	\$	455,227	\$	(297,743)
(Gain) loss on conversion of convertible debentures	\$	-	\$	-	\$	67,505	\$	67,505
(Gain) loss on repayment of convertible debentures	\$	-	\$	-	\$	-	\$	-
(Gain) loss on extinguishment of convertible debentures	\$	-	\$	53,483	\$	(39,142)	\$	14,341
<b>Unaudited Condensed Interim Consolidated Statement</b>	of Chang	ges in Equity						
Amount of principal converted to common shares	\$	-	\$	-	\$	524,600		
Amount of interest converted to common shares	\$	-	\$	-	\$	9,560		
Number of common shares issued on conversion of								
convertible debentures		-		-		18,834,053		18,834,053
<b>Unaudited Condensed Interim Consolidated Statement</b>	of Cash	Flows						
Amount of principal repaid in cash	\$	-	\$	7,490	\$	43,500	\$	50,990
Amount of interest repaid in cash	\$	11,925	\$	62,377	\$	1,500	\$	75,802
For the three months ended July 31, 2022:								
		USD		N (embedded	US	D (embedded		Total
Unaudited Condensed Interim Consolidated Statement	_		_					
Accretion expense	\$	6,913	\$	412,964	\$	2,342	\$	422,219
Interest expense	\$	60,451	\$	59,574	\$	4,245	\$	124,270
(Gain) loss on revaluation of derivative liabilities	\$	-	\$	339,989	\$	451,736	\$	791,725
(Gain) loss on conversion of convertible debentures	\$	-	\$	-	\$	(266,391)	\$	(266,391)
(Gain) loss on repayment of convertible debentures	\$	-	\$	-	\$	-	\$	- (20.542)
(Gain) loss on extinguishment of convertible debentures	\$	-	\$	-	\$	(30,642)	\$	(30,642)
(c) Fair value of derivative liabilities outstanding								
6				As at		As at		
				July 31,	(	October 31,		
				2023		2022		
Share price				\$0.10		\$0.03		
Exercise price			\$0	0.03 - \$0.07	\$	0.02 - \$0.07		
Volatility factor (based on historical volatility	y)		84	4% - 158%	14	40% - 232%		
Risk free interest rate			5.0	8% - 5.40%	3.0	09% - 4.28%		
Expected life of conversion features (in mon	ths)			0 - 11		0 - 11		
Expected dividend yield				0%		0%		
CDN to USD exchange rate (as applicable)				0.7589		0.7299		
C-11 -1 -			Φ.0	0.04 0.07	ф	0.00 00.00		

Volatility was estimated using the historical volatility of the Company's stock prices for common shares.

\$0.04 - \$0.07

\$0.00 - \$0.02

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

#### 10. Debenture payable

This debenture was issued on March 17, 2020 with an original maturity date of June 17, 2020 with a principal amount of \$51,500 CAD. On June 17, 2020, December 17, 2020, June 17, 2021, December 17, 2021, June 17, 2022, December 17, 2022 and June 17, 2023, the debenture was extended for six month intervals. The most recent extension on June 17, 2023, extended the debenture to December 17, 2023. The debenture bears interest at an annual rate of 24% and is unsecured. Interest expense on this debenture of \$2,296 USD and \$6,874 USD has been recognized during the three and nine months ended July 31, 2023 (2022 - \$2,286 USD and \$6,874 for the three and nine month periods).

# 11. Share capital

#### (a) Authorized and outstanding shares

The Company has two classes of shares as follows:

- (i) Special redeemable voting preference shares 2,000,000 authorized, nil issued and outstanding.
- (ii) Common shares without par value an unlimited number authorized. The holders of the common shares are entitled to receive dividends which may be declared from time to time, and are entitled to one vote per share at shareholder meetings of the Company. All common shares are ranked equally with regards to the Company's residual assets.

#### (b) Private placements

During the nine months ended July 31, 2023, the Company completed 23 private placements (2022 - 8 private placements), pursuant to prospectus and registration exemptions set forth in applicable securities law. The Company received net proceeds of \$498,690 (2022 - \$195,225) and issued a total of 9,239,500 (2022 - 4,513,674) common shares.

## 12. Stock options

#### (a) Stock option plan

Under the Company's fixed stock option plan (the "Plan"), the Company can grant up to 27,500,000 shares of common stock to directors, officers, employees or consultants of the Company and its subsidiaries. The exercise price of each option is equal to or greater than the market price of the Company's shares on the date of grant unless otherwise permitted by applicable securities regulations. An option's maximum term under the Plan is 10 years. Stock options are fully vested upon issuance by the Company unless the Board of Directors stipulates otherwise by Directors' resolution.

#### (b) Summary of changes

	Number of options	averag	eighted ge exercise price
Outstanding at October 31, 2022	11,725,000	\$	0.06
Granted (i)	3,000,000		0.09
Expired	(400,000)		0.10
Exercised	(2,550,000)		0.09
Outstanding at July 31, 2023	11,775,000	\$	0.06

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

## 12. Stock options (continued)

- (b) Summary of changes (continued)
- (i) The fair value of the options granted were determined in accordance with the Black-Scholes option-pricing model. The underlying assumptions are as follows:

Share price	\$0.07-\$0.12
Exercise price	\$0.07-\$0.12
Volatility factor (based on historical volatility)	175%-184%
Risk free interest rate	2.79%-3.58%
Expected life of options (in months)	12-60
Expected dividend yield	0%
Forfeiture rate	0%

(c) Stock options outstanding at July 31, 2023

-	-			Weighted average				
Date of issue	Expiry date	Options outstanding	Options exercisable	Exerc	cise price	Remaining contractual life		
November 13, 2020	November 13, 2025	5,750,000	5,750,000	\$	0.05	2.29		
October 8, 2021	October 8, 2026	1,000,000	1,000,000		0.07	3.19		
December 15, 2021	December 15, 2023	25,000	25,000		0.07	0.38		
October 11, 2022	October 11, 2023	2,000,000	1,500,000		0.07	0.20		
March 20, 2023	March 20, 2028	2,000,000	2,000,000		0.07	4.64		
April 6, 2023	April 6, 2024	1,000,000	250,000		0.12	0.68		
As at July 31, 2023		11,775,000	10,525,000	\$	0.06	2.27		

During the three and nine months ended July 31, 2023, the Company recorded an expense of \$nil and \$151,406 respectively for the vesting of stock options (2022 - \$nil and \$952). Of the 3,000,000 options granted during the year, 2,000,000 vested immediately on issuance.

 $Notes \ to \ the \ Unaudited \ Condensed \ Interim \ Consolidated \ Financial \ Statements$ 

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

### 13. Income (loss) per share

Basic and diluted income (loss) per share are calculated using the following numerators and denominators:

	Three months ended July 31,					Nine months ended July 31,			
Numerator		2023		2022		2023		2022	
Net loss attributable to common shareholders and used in						_			
computation of basic income (loss) per share	\$	149,612	\$	(1,421,173)	\$	(3,962,752)	\$	(2,706,177)	
Add: adjustments for dilutive effects		86,323				-		-	
Net loss attributable to common shareholders and used in computation diluted income (loss) per share	\$	235,935	\$	(1,421,173)	\$	(3,962,752)	\$	(2,706,177)	
Denominator									
Weighted average number of common shares for computation of basic income (loss) per share	503,800,902		426,218,016		480,136,985		447,023,410		
Dilutive effects of convertible features (Note 9) and stock options (Note 12)		93,275,927		-		-			
Weighted average number of common shares for computation of diluted income (loss) per share	4	597,076,829		426,218,016		480,136,985		447,023,410	

Basic income (loss) per share amounts are calculated by dividing the net income (loss) attributable to common shareholders for the periods by the weighted average number of common shares outstanding during the periods.

#### 14. Income taxes

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes.

As at July 31, 2023, the Company has non-capital losses of approximately \$32 million, \$27.6 million in Canada and \$4.4 million in other foreign jurisdictions, available to reduce future taxable income. Non-capital losses expire commencing in 2026. In addition, the Company has available capital loss carry forwards of approximately \$1.2 million to reduce future taxable capital gains. Capital losses carry forward indefinitely.

As at July 31, 2023, and October 31, 2022, the Company assessed that it is not probable that sufficient taxable income will be available to use deferred income tax assets based on operating losses in prior years; therefore, there are no balances recognized in the unaudited condensed interim consolidated statements of financial position for such assets.

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

# 15. Operating expenses

#### (a) General and administration

The components of general and administration expenses are as follows:

	Three months ended July 31,					Nine months ended July 31,				
		2023		2022		2023	2022			
General and administration	\$	30,135	\$	30,991	\$	60,011	\$	91,304		
Investor relations, listing and filing fees		9,520		11,888		49,122		60,061		
Telephone		1,302		1,937		3,782		5,581		
	\$	40,957	\$	44,816	\$	112,915	\$	156,946		

# (b) Professional, other fees and salaries

The components of professional, other fees and salaries expenses are as follows:

	T	Three months ended July 31,				Nine months ended July 31,				
	2023		2022		2023			2022		
Professional and consulting fees	\$	138,165	\$	86,011	\$	223,956	\$	241,735		
Salaries and benefits		47,871		92,162		158,382		262,253		
	\$	186,036	\$	178,173	\$	382,338	\$	503,988		

# 16. Supplemental cash flow information

The following provides a reconciliation of the cash flows from convertible debentures and derivative liabilities :

	Nine months ended July 31,				
		2023		2022	
Balance - beginning of period	\$	4,433,363	\$	3,239,483	
Cash flows from financing activities:					
Proceeds from issuance of convertible debentures		429,103		572,600	
Repayments of convertible debentures		(143,000)		(50,990)	
Non-cash changes:					
Accretion expense		221,801		1,677,162	
Accrued interest on convertible debentures		347,701		265,004	
Loss (gain) on repayment of convertible debentures		(33,349)		-	
Loss (gain) on conversion of convertible debentures		21,120		-	
Loss (gain) on revaluation of derivative liabilities		573,248		(297,743)	
Loss (gain) on extinguishment of debt		1,957,491		14,341	
Convertible debentures converted into common shares		(1,671,613)		(439,207)	
Renewal of convertible debentures		-		(11,043)	
Foreign exchange loss		56,000		185,680	
Balance - end of period	\$	6,191,865	\$	5,155,287	

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

#### 17. Key management compensation and related party transactions

The Company reports the following related party transactions:

#### (a) Key management compensation

Key management personnel are persons responsible for planning, directing and controlling activities of the Company, including officers and directors. Compensation paid or payable to these individuals (or companies controlled by such individuals) are summarized as follows:

	Three months ended July 31,				Nine months ended July 31,				
		2023		2022		2023		2022	
Professional, other fees, and salaries Stock-based compensation	\$	83,166	\$	41,317	\$	133,594 45,424	\$	105,307	
	\$	83,166	\$	41,317	\$	179,018	\$	105,307	

During the three and nine months ended July 31, 2023, key management was awarded 680,000 stock options (2022 - nil).

### (b) Trade payables and other liabilities

Included in accounts payable is \$5,150 CDN (USD - \$3,908) payable to a corporation controlled by an officer of the Company as at July 31, 2023 (October 31, 2022 - \$5,650 CDN (USD - \$4,139)).

#### 18. Contingencies

- (a) The Company has agreed to indemnify its directors and officers and certain of its employees in accordance with the Company's bylaws. The Company maintains insurance policies that may provide coverage against certain claims.
- (b) The Company has previously reported on the lawsuit filed by Mr. Steven Van Fleet against Micromem, the Company's response to the lawsuit and its counterclaims against Mr. Van Fleet.

On April 29, 2021 the matter was resolved in Micromem's favor when the Court dismissed Mr. Van Fleet's claims and ruled that he was liable to the Company and to MAST on their counterclaims. On June 16, 2021, the Court ruled that Micromem and MAST had established damages totaling \$765,579 representing the full amount that had been requested; furthermore, the Court awarded costs and statutory prejudgment interest from May 9, 2017. On June 29, 2021 the Court entered a judgement in favor of Micromem and MAST for a total amount of \$1,051,739.

With respect to the Company's efforts to collect on that Judgement, a settlement ("Settlement") was reached during October 2021. Pursuant to the Settlement, the Company received an initial one-time payment and is entitled to additional monthly payments over a period of up to six years. The Company will record those payments as and when they are received. The total amount to be received by the Company if Mr. Van Fleet makes all the required payments under the terms of the Settlement will be less than the amount of the Judgement obtained by the Company, but if Mr. Van Fleet does not comply with the terms of the Settlement, it also provides the Company a means of enforcing a larger judgement against Mr. Van Fleet that is substantially in line with the Judgement. Mr. Van Fleet has made the prescribed monthly payments each month since October 2021.

The Company is now pursuing collection of the judgement award. It will report the recovery of this contingent asset as funds are received. During the nine months ended July 31, 2023, the Company has recorded a recovery of \$8,920 received in the period as a reduction of legal expenses (2022 - \$4,800).

# Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

#### 19. Financial risk management

#### (a) Currency risk

Currency risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to currency risk to the extent that it incurs expenses and issues convertible debentures denominated in Canadian dollars (CDN). The Company manages currency risk by monitoring the Canadian dollar position of these monetary financial instruments on a periodic basis throughout the course of the reporting period.

As at July 31, 2023, and October 31, 2022, balances that are denominated in CDN are as follows:

	 As at July 31, 2023 CDN					
Cash	\$ 152,016	\$	15,715			
Other receivables	\$ 28,266	\$	13,832			
Trade payables and other liabilities	\$ 136,816	\$	393,978			
Convertible debentures	\$ 2,381,314	\$	2,810,362			
Debenture payable	\$ 51,500	\$	51,500			
Derivative liabilities	\$ 3,244,387	\$	601,696			
Long-term loan	\$ 60,000	\$	60,000			

A 10% strengthening of the US dollar against the CDN would decrease net loss and comprehensive loss by \$392,800 as at July 31, 2023 (October 31, 2022 - decrease net loss and comprehensive loss by \$257,995). A 10% weakening of the USD against the CDN would have the opposite effect of the same magnitude.

# (b) Interest rate risk

Interest rate risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market interest rates. The Company is exposed to interest rate risk on its interest-bearing convertible debentures. This exposure is limited due to the short-term nature of the convertible debentures.

#### (c) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. With the exception of the long-term loan, all financial liabilities are due within 1 year as at July 31, 2023.

#### (i) Trade payables

The following represents an analysis of the maturity of trade payables:

	July 31, 2023			October 31, 2022		
Less than 30 days past billing date	\$	103,830	\$	287,575		
31 to 90 days past billing date		-		-		
Over 90 days past billing date		=				
	\$	103,830	\$	287,575		

Ac at

Notes to the Unaudited Condensed Interim Consolidated Financial Statements

For the three and nine months ended July 31, 2023 and 2022

(Expressed in United States dollars, unless otherwise noted)

## 19. Financial risk management (continued)

#### (c) Liquidity risk (continued)

#### (ii) Convertible debentures and derivative liabilities

The following represents an analysis of the maturity of the convertible debentures and derivative liabilities:

	As at July 31, 2023						As at October 31, 2022					
	Convertible debentures		Derivative liabilities		Debenture payable		Convertible debentures		Derivative liabilities		Debenture payable	
Less than three months Three to six months Six to twelve months	\$	2,229,173 1,249,998 170	\$	1,715,692 807,527 189,305	\$	- - 39,486	\$	2,440,840 1,204,783 146,441	\$	162,380 257,933 220,986	\$	- - 38,001
	\$	3,479,341	\$	2,712,524	\$	39,486	\$	3,792,064	\$	641,299	\$	38,001

#### (d) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's cash. The maximum exposure to credit risk is the carrying value of these financial assets, which amounted to \$182,826 as at July 31, 2023 (October 31, 2022 - \$33,227). The Company reduces its credit risk by assessing the credit quality of counterparties, taking into account their financial position, past experience and other factors.

#### (i) Cash

The Company held cash of \$182,826 as at July 31, 2023 (October 31, 2022 - \$33,227). The cash is held with central banks and financial institution counterparties that are highly rated. The Company has assessed no significant change in credit risk and an insignificant loss allowance.

#### 20. Fair value hierarchy

Assets and liabilities recorded at fair value in the unaudited condensed interim consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities. There are no assets or liabilities in this category in these unaudited condensed interim consolidated financial statements.

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. In these unaudited condensed interim consolidated financial statements, derivative liabilities are included in this category.

Level 3 - valuation techniques using the inputs for the asset or liability that are not based on observable market data. There are no assets or liabilities in this category in these unaudited condensed interim consolidated financial statements.

The Company's policy for determining when transfers between levels of fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer. During the three and nine months ended July 31, 2023 and 2022, there were no transfers between levels.

Micromem Technologies Inc.
Notes to the Unaudited Condensed Interim Consolidated Financial Statements
For the three and nine months ended July 31, 2023 and 2022
(Expressed in United States dollars, unless otherwise noted)

### 21. Capital risk management

The Company's objectives when managing capital are to (i) maintain its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders, (ii) ensure it has sufficient cash resources to further develop and market its technologies and (iii) maintain its ongoing operations. The Company defines its capital as its net assets, i.e. total assets less total liabilities. In order to secure the additional capital necessary to pursue these objectives, the Company may attempt to raise additional funds through the issuance of equity or convertible debentures or by securing strategic partners. The Company is not subject to externally imposed capital requirements and there has been no change with respect to the overall capital risk management strategy during the three and nine month periods ended July 31, 2023.

#### 22. Subsequent events

Subsequent to July 31, 2023:

- (a) The Company secured a private placement with an investor consisting of common shares with no warrants pursuant to prospectus and registrations set forth in applicable securities law. It realized net proceeds of \$50,000 CDN and issued a total of 555,556 common shares.
- (b) The Company extended convertible debentures that were within 3 months of maturity date from July 31, 2023 for an additional six (6) months.
- (c) The Company secured \$55,938USD in a convertible debenture with a 12 month term and conversion features which become effective six months after initiation date.
- (d) The Company converted \$80,016 USD of convertible debentures, including interest, through the issuance of 1,143,092common shares.